Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38.
Exenatide
Not assigned in the current dataset.
FOXO4-DRI
FOXO4
Exenatide and FOXO4-DRI are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Exenatide is more often discussed in the realm of Metabolic and endocrine, whereas FOXO4-DRI is more often associated with the realm of Aging and longevity. Their biological logic is quite different: Exenatide is a receptor agonist, whereas FOXO4-DRI is a protein interaction inhibitor. Exenatide has a more venom-derived origin, while FOXO4-DRI is closer to synthetic design background and their development context also differs, with Exenatide approved while FOXO4-DRI is in Preclinical development. Exenatide carries amidation features, while FOXO4-DRI instead reflects retro-inverso isomerization changes, while their sequence patterns also diverge, with Exenatide showing alpha-helical domain features and FOXO4-DRI showing protein-mimetic sequence features.